Literature DB >> 31406413

In vitro therapeutic effect of Hemiscorpius lepturus venom on tachyzoites of Toxoplasma gondii.

L Khaleghi Rostamkolaie1, H Hamidinejat2, M H Razi Jalali2, H Jafari3, H Najafzadeh Varzi4, M R Seifi Abadshapouri2.   

Abstract

Pyrimethamine which is a main anti-Toxoplasma gondii drug has a serious side and toxic effects on the host. Accordingly, the development of new treatment options for toxoplasmosis with less toxic effects, low teratogenicity and parasiticidal effect against the various stage of T. gondii are dramatically crucial. Currently, natural molecules from scorpion and snake venoms are widely used as an alternative treatment against human disease, these compounds considered to be safe and to have low toxicity in comparison with synthetic drugs. Therefore, the goal of our study was to investigate the anti-Toxoplasma gondii activities of Hemiscorpius lepturus venom. We measured cytotoxicity of H. lepturus whole venom on Vero cells as well as effectiveness of this compound on viability of T. gondii applying colorimetric assay, according to mitochondrial oxidation of the MTT reagent (Methylthiazol tetrazolium 98%). The results of this study indicated that the H. lepturus whole venom has an anti-Toxoplasma effects with less toxic effect on Vero cells. Also, the T. gondii tachyzoites were treated with H. lepturus venom reached better results in comparison with Pyrimethamine-treated group. This research will serve as a base for future studies on toxoplasmosis and suggest a role for scorpion venom in promoting natural drugs.

Entities:  

Keywords:  Anti-parasitic, in vitro; Hemiscorpius lepturus venom; Scorpion; Toxoplasma gondii

Year:  2019        PMID: 31406413      PMCID: PMC6667720          DOI: 10.1007/s12639-019-01113-7

Source DB:  PubMed          Journal:  J Parasit Dis        ISSN: 0971-7196


  31 in total

1.  Scorpine, an anti-malaria and anti-bacterial agent purified from scorpion venom.

Authors:  R Conde; F Z Zamudio; M H Rodríguez; L D Possani
Journal:  FEBS Lett       Date:  2000-04-14       Impact factor: 4.124

2.  Antiproliferative activities of two novel quinuclidine inhibitors against Toxoplasma gondii tachyzoites in vitro.

Authors:  Erica S Martins-Duarte; Julio A Urbina; Wanderley de Souza; Rossiane C Vommaro
Journal:  J Antimicrob Chemother       Date:  2006-05-15       Impact factor: 5.790

3.  Recent advances in the search for new drugs for treatment of toxoplasmosis.

Authors:  F G Araujo; J S Remington
Journal:  Int J Antimicrob Agents       Date:  1992       Impact factor: 5.283

4.  Treatment of infants with congenital toxoplasmosis: tolerability and plasma concentrations of sulfadiazine and pyrimethamine.

Authors:  Dorte Remmer Schmidt; Birthe Hogh; Ole Andersen; Steen Honoré Hansen; Kim Dalhoff; Eskild Petersen
Journal:  Eur J Pediatr       Date:  2005-08-20       Impact factor: 3.183

5.  Toxoplasma gondii dysregulates IFN-gamma-inducible gene expression in human fibroblasts: insights from a genome-wide transcriptional profiling.

Authors:  Seon-Kyeong Kim; Ashley E Fouts; John C Boothroyd
Journal:  J Immunol       Date:  2007-04-15       Impact factor: 5.422

Review 6.  Toxoplasma gondii: from animals to humans.

Authors:  A M Tenter; A R Heckeroth; L M Weiss
Journal:  Int J Parasitol       Date:  2000-11       Impact factor: 3.981

7.  The molecular basis of sulfonamide resistance in Toxoplasma gondii and implications for the clinical management of toxoplasmosis.

Authors:  Tanya V Aspinall; David H M Joynson; Edward Guy; John E Hyde; Paul F G Sims
Journal:  J Infect Dis       Date:  2002-05-17       Impact factor: 5.226

8.  In vitro leishmanicidal activity of Tityus discrepans scorpion venom.

Authors:  Adolfo Borges; Sylvia Silva; Huub J M Op den Camp; Elena Velasco; Marco Alvarez; Marcelo J M Alfonzo; Alicia Jorquera; Leonardo De Sousa; Olinda Delgado
Journal:  Parasitol Res       Date:  2006-03-15       Impact factor: 2.289

9.  Temporal and spatial distribution of Toxoplasma gondii differentiation into Bradyzoites and tissue cyst formation in vivo.

Authors:  Manlio Di Cristina; Daniela Marocco; Roberto Galizi; Carla Proietti; Roberta Spaccapelo; Andrea Crisanti
Journal:  Infect Immun       Date:  2008-05-27       Impact factor: 3.441

Review 10.  The immunobiology of the innate response to Toxoplasma gondii.

Authors:  Catherine M Miller; Nicola R Boulter; Rowan J Ikin; Nicholas C Smith
Journal:  Int J Parasitol       Date:  2008-08-22       Impact factor: 3.981

View more
  2 in total

1.  Inhibition of Toxoplasma gondii Growth by Dihydroquinine and Its Mechanisms of Action.

Authors:  Aarin M Huffman; Joseph A Ayariga; Audrey Napier; Boakai K Robertson; Daniel A Abugri
Journal:  Front Cell Infect Microbiol       Date:  2022-05-11       Impact factor: 6.073

Review 2.  Antimalarial Agents as Therapeutic Tools Against Toxoplasmosis-A Short Bridge between Two Distant Illnesses.

Authors:  Alina Secrieru; Inês C C Costa; Paul M O'Neill; Maria L S Cristiano
Journal:  Molecules       Date:  2020-03-30       Impact factor: 4.411

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.